Halozyme Therapeutics (NASDAQ:HALO) Issues Earnings Results

Halozyme Therapeutics (NASDAQ:HALO) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported $2.28 earnings per share for the quarter, topping the consensus estimate of $1.79 by $0.49, FiscalAI reports. Halozyme Therapeutics had a return on equity of 232.11% and a net margin of 24.86%.The firm had revenue of $481.00 million for the quarter, compared to analysts’ expectations of $402.28 million. During the same quarter last year, the business earned $1.54 EPS. The company’s quarterly revenue was up 47.7% compared to the same quarter last year. Halozyme Therapeutics updated its FY 2026 guidance to 8.650-9.000 EPS.

Here are the key takeaways from Halozyme Therapeutics’ conference call:

• Record second-quarter performance: Total revenue rose 48% year over year to $481 million, while royalty revenue increased 50% to $307.7 million. Adjusted EBITDA reached $328.8 million and non-GAAP EPS was $2.28.
• 2026 guidance was raised: Halozyme now expects total revenue of $1.835 billion-$1.91 billion, royalty revenue of $1.22 billion-$1.245 billion, adjusted EBITDA of $1.225 billion-$1.28 billion, and non-GAAP EPS of $8.65-$9.00.
• ENHANZE product diversification accelerated: Royalties from newer launches—including OCREVUS ZUNOVO, Opdivo Qvantig, and RYBREVANT SC—increased approximately 80% sequentially, complementing continued growth from DARZALEX SC, VYVGART Hytrulo, and PHESGO.
• Strong partnership momentum expanded the long-term pipeline: Halozyme signed five collaboration and licensing agreements across the quarter and July, including deals with GSK, Incyte, Vertex, and Oruka, generating $35.5 million in upfront revenue and expanding ENHANZE into ADCs and nucleic-acid therapies.
• Litigation remains an important uncertainty: Halozyme is pursuing injunctions against Merck in roughly eight countries and plans to appeal four U.S. patent-review decisions, although management expressed strong confidence it will ultimately prevail.

Halozyme Therapeutics Price Performance

HALO stock opened at $103.12 on Friday. The company’s 50-day moving average price is $76.48 and its two-hundred day moving average price is $71.47. The firm has a market cap of $12.23 billion, a P/E ratio of 30.78, a P/E/G ratio of 0.36 and a beta of 0.85. The company has a quick ratio of 2.33, a current ratio of 2.76 and a debt-to-equity ratio of 8.81. Halozyme Therapeutics has a 12 month low of $61.22 and a 12 month high of $103.30.

Insider Transactions at Halozyme Therapeutics

In related news, Director Mahesh Krishnan sold 7,304 shares of the stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the sale, the director owned 14,462 shares in the company, valued at approximately $1,084,650. This trade represents a 33.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 1,923 shares of the business’s stock in a transaction that occurred on Wednesday, July 8th. The shares were sold at an average price of $79.77, for a total transaction of $153,397.71. Following the transaction, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $61,245,810.60. This represents a 0.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 72,477 shares of company stock valued at $5,102,643. Company insiders own 2.50% of the company’s stock.

Institutional Trading of Halozyme Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Corient Private Wealth LLC grew its position in Halozyme Therapeutics by 1,552.5% in the fourth quarter. Corient Private Wealth LLC now owns 196,329 shares of the biopharmaceutical company’s stock valued at $13,213,000 after acquiring an additional 184,448 shares during the last quarter. Caitlin John LLC bought a new position in shares of Halozyme Therapeutics in the fourth quarter worth about $465,000. First Citizens Bank & Trust Co. lifted its holdings in shares of Halozyme Therapeutics by 2.8% in the fourth quarter. First Citizens Bank & Trust Co. now owns 8,913 shares of the biopharmaceutical company’s stock worth $600,000 after acquiring an additional 242 shares during the last quarter. State of Tennessee Department of Treasury boosted its stake in shares of Halozyme Therapeutics by 38.9% in the 4th quarter. State of Tennessee Department of Treasury now owns 57,516 shares of the biopharmaceutical company’s stock valued at $4,124,000 after purchasing an additional 16,105 shares in the last quarter. Finally, EP Wealth Advisors LLC acquired a new stake in shares of Halozyme Therapeutics in the 4th quarter valued at approximately $592,000. 97.79% of the stock is currently owned by institutional investors.

Trending Headlines about Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Record Q2 results beat expectations: Halozyme reported adjusted earnings of $2.28 per share, above the roughly $1.79-$1.82 consensus, while revenue rose 48% year over year to $481 million versus estimates near $402 million. Royalty revenue increased 50% to $308 million. Halozyme reports record second quarter 2026 results
• Positive Sentiment: 2026 guidance was raised: Management now expects revenue of $1.835 billion-$1.910 billion, royalty revenue of $1.220 billion-$1.245 billion, adjusted EBITDA of $1.225 billion-$1.280 billion and non-GAAP EPS of $8.65-$9.00. The EPS range is above the approximately $8.02 analyst consensus. Halozyme Q2 earnings beat estimates
• Positive Sentiment: Commercial momentum expanded: Halozyme signed five new ENHANZE and Hypercon collaboration agreements year to date, exceeding its full-year goal of three. The agreements support the company’s royalty-driven platform model and broaden future revenue opportunities.
• Positive Sentiment: Analyst sentiment improved: Leerink Partners upgraded HALO to “outperform” with a $110 price target. HC Wainwright raised its target to $115 and retained a “buy” rating, while TD Cowen increased its target to $105 and also rated the stock “buy.”
• Neutral Sentiment: Analyst views remain mixed at the elevated valuation: Citizens JMP raised its target to $93 with a “market outperform” rating, and Wells Fargo lifted its target to $95 while maintaining “equal weight.” Both targets remain below the recent trading level, suggesting some analysts see limited near-term upside.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on HALO shares. Wall Street Zen raised shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Morgan Stanley decreased their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. Citizens Jmp raised their target price on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a “market outperform” rating in a report on Friday. Finally, Citigroup reiterated a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Friday. Nine equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $91.20.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.